# Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

> **NCT02115750** · PHASE3 · COMPLETED · sponsor: **Coherus Oncology, Inc.** · enrollment: 647 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** CHS-0214

## Key facts

- **NCT ID:** NCT02115750
- **Lead sponsor:** Coherus Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-10
- **Final completion:** 2016-05
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2019-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02115750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02115750, "Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02115750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*